Journal
ONCOGENE
Volume 40, Issue 28, Pages 4663-4674Publisher
SPRINGERNATURE
DOI: 10.1038/s41388-021-01893-4
Keywords
-
Funding
- Scientific research and cultivation project of talents in the First Affiliated Hospital of Nanchang University [YFYPY202015]
Ask authors/readers for more resources
The study revealed the mechanism of overexpression of Plk1 in pancreatic cancer (PC) and explored the potential therapeutic strategy of targeting vaccinia-related kinase 2 (VRK2) as a treatment target.
As a key cell cycle regulator, polo-like kinase 1 (Plk1) has been recognized as a crucial factor involved in the progression of pancreatic cancer (PC). However, its regulatory mechanism is poorly understood. Here, we present evidence that Plk1 is a novel substrate of vaccinia-related kinase 2 (VRK2), a serine-threonine kinase that is highly expressed and predicts poor prognosis in PC. VRK2 phosphorylates Plk1 at threonine 210 and protects it from ubiquitin-dependent proteasomal degradation. We showed that mechanistically complement factor H-related protein (CFHR), as a major E3 ligase, promotes Plk1 degradation by ubiquitinating it at lysine 209. Phosphorylation of Plk1 at threonine 210 by VRK2 interferes with the interaction of Chfr with Plk1 and antagonizes Plk1 ubiquitination, thereby stabilizing the Plk1 protein. Taken together, our data reveal a mechanism of Plk1 overexpression in PC and provide evidence for targeting VRK2 as a potential therapeutic strategy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available